Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026

view original post

Akebia Therapeutics’ Vafseo expansion may boost future growth despite Auryxia’s exclusivity loss. Read why AKBA stock is rated a hold.